Independent DSMB recommends continuing clinical trial of Berubicin without modificationEnrollment expected to be complete in early Q1 2024HOUSTON, TX /…
ANN ARBOR, MI / ACCESSWIRE / December 18, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary…
LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on…
New AI-Driven Platform to Transform Clinical Outcomes Assessment: COA-AI Software Merges AI Efficiency with Researcher ExpertiseTUCSON, AZ / ACCESSWIRE /…
This Calls for a CelebrationHouston, Texas--(Newsfile Corp. - December 15, 2023) - On December 5, 2023, Cannabis Bioscience International Holdings…
- Stanford Medicine, a center with a long tradition of leadership in pioneering gynecological research and innovation, is the second…
FORWARD-53 is fully enrolled with potentially registrational dystrophin expression data expected in 2024 Previous clinical proof-of-concept data demonstrated highest level…
VANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional…
BOSTON, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today…
AC Immune Announces Pricing of Underwritten Offering of Common Shares Lausanne, Switzerland, December 15, 2023 – AC Immune SA (Nasdaq:…